Business UpdateJul 13, 2026, 08:02 AM
Picard Medical Q1 Revenue +85%; Advances Emperor Heart Platform
AI Summary
Picard Medical announced the availability of its pre-recorded presentation for the 2026 Annual Meeting of Stockholders. The presentation highlighted strong Q1 2026 financial performance, with revenue increasing 85% year-over-year and US revenue up 116%. Gross margin improved significantly to 24% from -4% in 2025. The company also provided updates on its next-generation Emperor platform, targeting FDA Breakthrough Device designation and clinical studies by 2029 for a fully implantable artificial heart.
Key Highlights
- Q1 2026 revenue increased 85% year-over-year.
- US revenue for Q1 2026 surged 116%.
- Gross margin for Q1 2026 was 24%, up from -4% in 2025.
- Next-gen Emperor platform aims for fully implantable artificial heart.
- Plans for FDA Breakthrough Device designation for Emperor platform.
- Investigational Device Exemption (IDE) submission planned for 2028.
- Clinical study activities for Emperor platform targeted for 2029.
- Annual Meeting of Stockholders scheduled for July 17, 2026.
Price Impact
More from PMI